Terrapeutics focuses on discovering novel therapeutic solutions from soil-based microorganisms.

Its groundbreaking discovery technology combines synthetic biology, sequencing tools, and computational biology to utilize soil's full potential to discover novel small molecules that can tackle 'undruggable' targets.

It does that, by disrupting a natural environment in soil with an engineered microorganism (according to the pre-defined drug target aims to tackle) that threatens that environment.

This threat forces its residents to respond by producing small molecules against the drug target we are aiming at.

The results show that this technology identifies the specific drug-producing bacteria and the genes associated with such activity with high success rates.

The company's lead discovery program focuses on pan KRAS inhibitors, the next generation of solutions for a target that drives 25% of cancers.

Through KRAS discovery program, the company has proven its ability to solve two critical bottlenecks in soil-based drug discovery – the ability to swiftly identify drug-producing bacteria and the associated biosynthetic gene clusters against a pre-defined drug target as challenging as it can get.

In addition, the discovery platform can uniquely tackle two major classes of undruggable targets: protein-protein interactions like p53-MDM2 and transcription factors like c-Myc.

We plan to add such discovery programs shortly.